Loss of function of retinol dehydrogenase 11 causes a recessive syndrome characterized by myopathy, retinal dystrophy, juvenile cataracts, and microcephaly.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Radio Francesca Clementina, Tasca Giorgio, Coppens Sandra, Chillemi Giovanni, Whalen Sandra, Marey Isabelle, Leoni Chiara, Onesimo Roberta, Deconinck Nicolas, D'Amico Adele, Remiche Gauthier, Nascimento Andres, Ortez Carlos, Jou Cristina, Lecomte Sophie, Falsini Benedetto, Ciolfi Andrea, Ferilli Marco, Cappelletti Camilla, Niceta Marcello, Gowda Vykuntaraju K, Srinivasan Varunvenkat M, Vahidi Mehrjardi Mohammad Yahya, Dadbinpour Ali, Movahedinia Mojtaba, Firoozfar Zahra, Alavi Shahryar, Alibakhshi Reza, Ghazinader Donya, Mojarrad Majid, Rajati Mohsen, Keren Boris, Bertini Enrico Silvio, Zampino Giuseppe, Natera de Benito Daniel, Maroofian Reza, Tartaglia Marco
Аннотация
METHODS: In the frame of a collaborative effort, clinical and molecular data were collected using a semistructured survey. Structural modeling of RDH11 with NADH(P) was used to assess the functional impact of missense variants.
RESULTS: Sixteen affected individuals from 9 unrelated families with biallelic RDH11 variants were assembled, frequently showing juvenile-onset progressive myopathy with vacuolar degeneration and prodromic asymptomatic hyperCKemia. Neurodevelopmental impairment, juvenile-onset cataract, and retinal dystrophy were confirmed as common features. Microcephaly and distinct craniofacial traits were also recurrent, whereas short stature was less frequent than previously reported. Most pathogenic variants were truncating, supporting RDH11 loss of function as the mechanism of disease. Consistently, the identified missense changes were predicted to affect RDH11 catalytic function.
CONCLUSION: We refine the clinical and molecular spectra of RDH11-related disorder, reclassifying it as syndromic intellectual disability with muscular (juvenile myopathy) and ocular (retinal dystrophy) involvement. These insights are expected to improve diagnostic accuracy and patient care, guiding clinical evaluation, and genetic counseling.